Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma
Large and small ccRCCs are genomically different. Aggressive mutations, namely, SETD2, BAP1, and CDKN2A loss, are rarely observed in small ccRCCs and are observed more frequently in larger tumours. However, when present in tumours ≤7 cm, SETD2 mutations and CDKN2A loss were still independently associated with invasive disease, metastasis, worse survival, and recurrence after resection, after controlling for size.
Authors
- Benjamin W. Carney (ORCID: https://orcid.org/0000-0002-4547-0503)
- Steven Monda (ORCID: https://orcid.org/0000-0002-8548-8193)
- Shuchi Gulati (ORCID: https://orcid.org/0000-0001-6793-9694)
- Thenappan Chandrasekar (ORCID: https://orcid.org/0000-0002-2173-5028)
- Ganesh S. Palapattu (ORCID: https://orcid.org/0000-0002-9520-0480)
- Evan T. Keller (ORCID: https://orcid.org/0000-0002-7592-7535)
- Allison M. May
- Simpa S. Salami (ORCID: https://orcid.org/0000-0001-7461-7079)
- Nicolai Huebner (ORCID: https://orcid.org/0000-0002-1256-1927)
- Marc Dall’Era (ORCID: https://orcid.org/0000-0002-2301-2683)
Institutions
- University of Michigan (US)
- Medical University of Vienna (AT)
- University of California, Davis (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1111/bju.16527
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- National Institutes of Health
- National Cancer Institute